Log in Subscribe

Higher persisting seroprotection rates in subjects boosted at Year 5 did not translate into apparent differences in immune memory in a high endemic with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)

Saleh Barrett
· 3 min read
Higher persisting seroprotection rates in subjects boosted at Year 5 did not translate into apparent differences in immune memory in a high endemic with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)

transplant recipients has not been assessed. Seventy-five patients (37 kidney transplant [KT] recipients and 38 healthy controls) received two doses, at 4-week intervals, of an inactivated whole-virus SARS-CoV-2 vaccine. SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity (CMI) were measured before, 4 weeks post-first dose, and 2 weeks post-second dose. The median (IQR) age of KT recipients was 50 (42-54) years and 89% were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median (IQR) time since transplant was 4.5 (2-9.

5) years. Among 35 KT patients, the median (IQR) of anti-RBD IgG level measured by CLIA after vaccination was not different from baseline, but was significantly lower than in controls (2.4 [1.1-3.7] vs. 1742.0 [747.

7-3783.0] AU/ml, p < .01) as well as percentages of neutralizing antibody inhibition measured by surrogate viral neutralization test (0 [0-0] vs. 71.2 [56.8-92.2]%, p < .

01). However, the median (IQR) of SARS-CoV-2 mixed peptides-specific T cell responses measured by ELISpot was significantly increased compared with baseline (30 [4-120] vs. 12 [0-56] T cells/10(6)  PBMCs, p = .02) and not different from the controls. Our findings revealed weak HMI but comparable CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccination compared to immunocompetent individuals (Thai Clinical Trials Registry, TCTR20210226002).Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.Transplantation and the American Society of Transplant SurgeonsAGAINST CERTAIN SEROTYPES OF GROUP A STREPTOCOCCI.

Harrell. New method of preparing immunizing antigens for the production of anti-M sera against certain serotypes of group A streptococci. J. Bacteriol. 89:141-145. 1965.-Antisera against types 4, 29, 41, and 46 streptococci have been prepared by use of a vaccine killed by adjusting the pH to 11.

7 and heating for 1 hr at 56 C. Heating at the high pH destroyed the antigenic material responsible for the major reciprocal crosses present in cells of types 4, 29, and 46 without affecting the M protein. Antisera prepared with the "alkaline-treated" vaccine did not contain the major reciprocal crosses. Antibodies against the M protein were shown to be present by the bactericidal test, failure to react in the precipitin test with acid extracts of homologous trypsinized cells, and retention of the precipitin reaction after absorption with homologous trypsinized cells.  aloe emodin supplement  did not react with the "B" antigen of the provisional type B 3264. Type 11 antisera prepared with alkaline-treated vaccine did not contain antibodies against the M protein. The usefulness of this type vaccine, particularly for the preparation of type 4 antiserum, is discussed, as well as its limitations.

inoculated according to a disrupted vaccination schedule].s narusheniem grafika vaktsinatsii.born from cows vaccinated with the MB 113 strain].Vaccination des veaux nés de mères elles-mêmes vaccinées avec la souche MB 113.administration of SARS-CoV-2 RBD epitope peptide-based immunogen In vivo.the socio-economic conditions all over the world. The disease is caused by SARS-CoV-2 virus that belongs to the family of Coronaviruses which are known to cause a wide spectrum of diseases both in humans and animals.

One of the characteristic features of the SARS-CoV-2 virus is the high reproductive rate (R(0)) that results in high transmissibility of the virus among humans. Vaccines are the best option to prevent and control this disease. Though,  Order now  (IM) route of vaccine administration is one of the effective methods for induction of antibody response, a needle-free self-administrative intradermal (ID) immunization will be easier for SARS-CoV-2 infection containment, as vaccine administration method will limit human contacts. Here, we have assessed the humoral and cellular responses of a RBD-based peptide immunogen when administered intradermally in BALB/c mice and side-by-side compared with the intramuscular immunization route.